June 10, 2016
Source: ACT Press Release
The Alliance for Children's Therapeutics today presented positive, updated data from an ex vivo study using KPI's Therapeutics/Kineta's lead drug Dalazatide for children and teens with lupus nephritis. The results were presented at the European League Against Rheumatism's 17th Annual Congress in London. Dr. Anne Stevens, a researcher at the Seattle Children's Research Institute, is leading the study and presented the work at the congress...
"New study data shows that patients with active lupus nephritis express higher levels of the Kv 1.3 channel, the target of Dalazatide, than do patients with inactive disease or healthy volunteers," said Dr. Stevens. "T cells from patients with active lupus are sensitive to blockade by Dalazatide, demonstrating ex vivo efficacy of the drug, and provide data to support the design of a clinical trial in patients with lupus, she added. More